Uncategorized
Ora-CAC® Model Delivers Successful Phase 3 Data for Ocular Therapeutix’s DEXTENZA™ (OTX-DP) for Treatment of Allergic Conjunctivitis
ANDOVER, Mass.--(BUSINESS WIRE)--Conjunctival Allergen Challenge model recently confirmed Phase 2 clinical results of Sustained Release Dexamethasone, a drug-eluting intracanalicular depot, under development by Ocular Therapeutix
